Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 592,354,240
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 33,724 M
  • Annual Income, $ 12,151 M
  • 60-Month Beta 0.42
  • Price/Sales 18.23
  • Price/Cash Flow 45.50
  • Price/Book 37.86
Trade NVO with:

Options Overview Details

View History
  • Implied Volatility 31.90% ( -1.75%)
  • Historical Volatility 43.83%
  • IV Percentile 59%
  • IV Rank 33.27%
  • IV High 49.01% on 08/05/24
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 0.55
  • Today's Volume 13,877
  • Volume Avg (30-Day) 16,027
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 275,526
  • Open Int (30-Day) 262,412

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.91
  • Number of Estimates 4
  • High Estimate 0.97
  • Low Estimate 0.87
  • Prior Year 0.73
  • Growth Rate Est. (year over year) +24.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
128.40 +2.85%
on 09/10/24
139.74 -5.49%
on 08/30/24
-2.83 (-2.10%)
since 08/16/24
3-Month
118.80 +11.16%
on 08/07/24
148.15 -10.86%
on 06/25/24
-8.74 (-6.21%)
since 06/18/24
52-Week
86.96 +51.86%
on 10/03/23
148.15 -10.86%
on 06/25/24
+38.75 (+41.54%)
since 09/18/23

Most Recent Stories

More News
Tap the Weight-Loss Drug Market With These ETFs

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...

RHHBY : 39.6100 (+0.71%)
NVO : 132.06 (+0.05%)
LLY : 904.97 (-0.13%)
HRTS : 34.67 (+0.14%)
THNR : 27.38 (-0.07%)
OZEM : 28.15 (-0.60%)
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?

Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The stock has also outperformed the sector as well as the S&P 500 as seen in the chart...

BIIB : 197.59 (-0.31%)
NVO : 132.06 (+0.05%)
LLY : 904.97 (-0.13%)
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)

Telemedicine once seemed like it was going to revolutionize healthcare.

LLY : 904.97 (-0.13%)
PFE : 29.75 (-0.27%)
NVO : 132.06 (+0.05%)
TDOC : 9.09 (-0.22%)
AMZN : 186.43 (-0.24%)
NVDA : 113.37 (-1.92%)
SFIX : 4.14 (+0.98%)
VKTX : 64.45 (+2.40%)
ALT : 7.43 (-1.85%)
RHHBY : 39.6100 (+0.71%)
HIMS : 16.31 (+1.30%)
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200

No need to break the bank to get in on these excellent companies.

NVO : 132.06 (+0.05%)
DXCM : 69.46 (+0.75%)
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

This week, the FDA approved J&J’s JNJ Tremfya for treating an inflammatory bowel disease condition (“IBD”), ulcerative colitis. Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight...

REGN : 1,138.81 (-0.69%)
SNY : 57.47 (+0.98%)
JNJ : 166.15 (-0.55%)
NVO : 132.06 (+0.05%)
Why Investors Plowed Into Viking Therapeutics Stock Today

The company is looking especially good after some bad news coming from a rival.

MS : 99.30 (-0.54%)
VKTX : 64.45 (+2.40%)
NVO : 132.06 (+0.05%)
LLY : 904.97 (-0.13%)
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug

Roche RHHBY presented results of an early-stage study on its experimental obesity drug, CT-996, at the European Association for the Study of Diabetes annual meeting.CT-996 is an investigational, once-daily,...

RHHBY : 39.6100 (+0.71%)
NVO : 132.06 (+0.05%)
LLY : 904.97 (-0.13%)
3 No-Brainer Biotech Stocks to Buy With $200 Right Now

An investment in these players today could score a big win down the road.

LLY : 904.97 (-0.13%)
GS : 484.58 (-0.17%)
NVO : 132.06 (+0.05%)
VKTX : 64.45 (+2.40%)
MRNA : 69.86 (-2.96%)
CRSP : 49.59 (-0.56%)
Why Roche Holdings Stock Withered on Wednesday

The company had a dispiriting update to offer about an investigational drug.

NVO : 132.06 (+0.05%)
LLY : 904.97 (-0.13%)
RHHBY : 39.6100 (+0.71%)
Why Viking Therapeutics Stock Rocked the Market Today

The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug.

LLY : 904.97 (-0.13%)
JPM : 207.53 (-0.82%)
NVO : 132.06 (+0.05%)
VKTX : 64.45 (+2.40%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 135.09
2nd Resistance Point 134.18
1st Resistance Point 133.12
Last Price 132.06
1st Support Level 131.15
2nd Support Level 130.24
3rd Support Level 129.18

See More

52-Week High 148.15
Last Price 132.06
Fibonacci 61.8% 124.78
Fibonacci 50% 117.55
Fibonacci 38.2% 110.33
52-Week Low 86.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar